BURLINGTON, North Carolina -- LabCorp has received emergency use authorization from the Food and Drug Administration for its Pixel at home coronavirus test kit. The COVID-19 At Home Test Kit allows ...

The FDA has authorized the first diagnostic test with a home collection option for COVID-19, the disease caused by coronavirus. In a statement released Tuesday, the FDA said that it had reissued an ...

North Carolina’s LabCorp has gotten the federal go-ahead for an at-home testing kit for COVID-19, the new coronavirus. It’s the first authorized by the Food and Drug Administration. LabCorp of ...

(NEW YORK) — As COVID-19 test positivity rates resurged in recent weeks, private test providers have made efforts to sound the alarm that the rising demand for testing may outpace their ability to ...

As a leading independent diagnostic laboratory, LabCorp participates in a highly attractive duopoly that offers bright prospects as healthcare moves toward reformed payment models, despite current ...

Labcorp (NYSE:LH) posted its fourth consecutive quarterly revenue decline on Thursday, estimating up to a 90% decline in its COVID testing revenue this year amid the waning pandemic impact. However, ...

But even Labcorp and Quest have limits to how many test machines they can afford. As publicly traded companies that must return profits to shareholders, they can’t invest tens of millions of dollars ...

Laboratory Corporation of America Holdings or Labcorp LH is entangled in the current economic uncertainty due to a challenging volume environment for testing laboratories and utilization weaknesses.

(Reuters) -Laboratory Corp of America Holdings on Thursday predicted that COVID testing sales could fall by up to 90% this year after nearly two years of a boost to its diagnostics unit during the ...

Shares of Laboratory Corporation of America Holdings LH were down about 2.9% in premarket trading on Thursday after the diagnostics company reported lower-than-expected revenue in the fourth quarter ...

LabCorp delivered third-quarter results that closely track with our full-year topline expectations. Gross margin year-to-date has run slightly behind our projections, but that was partially offset by ...